Allergy:过敏性鼻炎中CD23的表达建立T-B细胞互作

2020-04-17 AlexYang MedSci原创

B细胞亚群和T-B细胞互作对过敏性鼻炎的贡献以及过敏原免疫治疗(AIT)的机制仍旧了解甚少。最近,有研究人员在AR患者中探究了循环B细胞特征、潜在机制和与AIT临床响应相关性。

B细胞亚群和T-B细胞互作对过敏性鼻炎的贡献以及过敏原免疫治疗(AIT)的机制仍旧了解甚少。最近,有研究人员在AR患者中探究了循环B细胞特征、潜在机制和与AIT临床响应相关性。

研究发现,在AR患者中,循环记忆B细胞的频率和绝对数量增加;CD23在CD19+ CD20+ CD27+ IgD-开关记忆B细胞中的表达显著增强,并且与抗原特异性lgE水平、症状得分和Tfh2/Tf细胞比例有关。与健康对照相比,AR患者的Tfh2细胞通过IL-4诱导开关记忆B细胞CD23表达的能力更强,并且不能被AR相关的具有IL-10表达缺陷的Tfr细胞充分抑制。在12个月的AIT治疗后,AR患者中开关记忆B细胞的CD23表达下调,且与疾病减轻正相关。

最后,研究人员指出,在AR患者中,CD23表达搭建的T-B细胞互作参与了疾病病理和AIT机制。

原始出处:

Yao Y, Wang N, Chen CL et al. CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy. 21 Mar 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-19 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-19 ylz8405
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-18 1902498648_44512810

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2047246, encodeId=7902204e2468d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 17 04:39:24 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329361, encodeId=9482132936153, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471658, encodeId=606014e1658ee, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Apr 19 04:39:24 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381863, encodeId=13de38186358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Sat Apr 18 18:30:04 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381807, encodeId=46d038180e67, content=论文期刊联系V(jiaowobabb), beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f465319451, createdName=康庄, createdTime=Fri Apr 17 14:27:52 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-17 康庄

    论文期刊联系V(jiaowobabb)

    0

相关资讯

Nature:新型免疫细胞“动员”T细胞,更有效抗击“癌症之王”胰腺癌

2月19日,来自美国纪念斯隆-凯特琳癌症中心的研究小组报告发现了一个“候选”:一组被称为先天淋巴样细胞(ILCs)的免疫细胞。相关研究结果发表在《Nature》杂志上。

Cell Death Dis:病毒感染时,Top2α诱导端粒DNA损伤导致T细胞功能障碍

T细胞在病毒感染控制中起着至关重要的作用。既往研究表明,慢性病毒感染可导致T细胞过早衰老及免疫衰老。然而,调节这些反应的机制尚有待研究。

Oncogene:p300/CBP抑制剂能够增强前列腺中程序性死亡配体1阻断治疗的效果

抗体药物的程序性死亡配体1(PD-L1)阻断在癌症治疗中是一种很有前景的治疗方法,而在许多类型癌症的临床响应,包括前列腺癌(PCa)仍旧有限。肿瘤细胞通过外泌体或者剪接变异分泌PD-L1,并且在许多类

Biol Pharm Bull:过敏性鼻炎中T细胞介导的鼻高反应性

过敏性鼻炎患者承受着各种各样的症状,比如打喷嚏、流鼻涕和鼻塞。随着疾病严重度和慢性进展,鼻高反应性(NHR)能够在这些患者产生和发展。最近,有研究人员在开发一个小鼠过敏性鼻炎模型中,发现了免疫小鼠在进行重复的鼻抗原挑战时能够发展为NHR。通过使用遗传修饰小鼠和一个原始开发的T细胞转移小鼠模型,研究人员确认了NHR中分化为几种辅助细胞后CD4+T细胞的关键作用。从另一方面来讲,免疫球蛋白E/肥大细胞

Eur Arch Otorhinolaryngol:调控T细胞在过敏性鼻炎中的作用研究

过敏性比亚(AR)是一种lgE介导的鼻部炎症。调控T细胞(Tregs)和炎症细胞因子在过敏性气道炎症中具有关键的作用。最近,有研究人员在AR患者和健康对照中,比较了血液T淋巴细胞亚群水平以及血清和鼻灌洗液中IL-10、IL-17和新蝶呤浓度情况。研究包括了38名患有中度到重度的AR受试者和36名性别和年龄匹配的对照。研究人员利用流式细胞仪对外周血CD3+、CD3+CD4+和CD4+CD25+Fox

Carl Juno团队发表在Science上的新研究表明,CRISPR基因编辑后的T细胞在癌症患者中可存活数月

发表在Science杂志上的1期临床试验结果,证明CRISPR-Cas9基因编辑后的T细胞在患者体内可以保留几个月。并且分离接受治疗数月后患者体内基因编辑后的T细胞,在体外进行实验时仍然可以杀死癌症。